Avid Bioservices Inc (CDMO)

[biopharm]

Must See Presentation..Dmitry Gabrilovich : Peregrine Pharmaceuticals KOL : ... the bottom line, Dmitry is the MD talking MDSC's and MDSC's "CAN" predict overall survival and he starts off the video with some general talking points re: leucocytes/neutrophils .. immune system..etc before showing in various cancer indications-- its MDSC's that speak the truth about overall survival.

Do I really think the the DMC will allow SunRise to go further than it needs to, once PS Targeting is proven to fall directly inline with positioning MDSC's on that path of a positive overall survival? Nope

I believe Dmitry is playing a major role in solidifying the changes that take place regarding our immune systems and most likely this will all play a part in some blood test to test for cancer in general due to many changes... some involving white blood cells aka = leucocytes (which there are 5 types)

1) Neutrophils
2) Eosinophils
3) Basophils
4) Monocytes
5) Lymphocytes - just will expand on this for now..

Two main types of lymphocytes are B-cells and T-cells. B-cells are characterized by the presence of immunoglobulins on their surface, and upon stimulation with antigen, they are transformed into plasma cells. Plasma cells are then able to secrete antibodies specific to the antigen. T-cells take part in cell mediated immune response, which does not depend on the presence of circulating antibodies.

bme.virginia.edu/ley/leukocytes.html

older post... been harping on these leucocytes/blood test for a while now...

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=94362010&txt2find=leucocytes

1st Annual Summit on Practical Applications of Immune and Oncolytic Therapies in Oncology

The role of myeloid-derived suppressor cells as a therapeutic target

.... now the entire presentation you need to watch. Dmitry even gets the crowd laughing a bit at the end : ) though, I like the part leading up to the 8 min mark:

MDSC as predictors of clinical outcome in cancer:

Melanoma:

* Clinical responders to ipilimumab therapy showed significantly less MDSC as compared to non-responders. MDSC may be used as predictive marker of response

* Frequency of MDSC correlated with disease progression and decreased overall survival.

* ....
....

---------------------------------------------------

1st Annual Summit on Practical Applications of Immune and Oncolytic Therapies in Oncology

.. July 18-20 at "The Breakers Hotel" in Palm Beach, FL

https://www.mdlinx.com/oncology/conference-details.cfm/86008/

.....now, just remember the biopsies that Peregrine has been collecting. My oh my.... those MDSC's just may certainly drive Big Pharma in circles trying to figure out what to do with little old Peregrine... : )

Maybe a last minute deal on Peregrines terms could be in the works... but it would only be possible with a Big Pharma with their back on the ropes-- GSK?

http://uk.reuters.com/article/2014/07/23/breakingviews-gsk-idUKL6N0PY4Y220140723